You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Hero image

A COMPLETE REGIMEN OFFERING CONVENIENT DOSING FOR YOUR PATIENTS 2

 Icon once daily

ONE PILL,
ONCE A DAY

24 hours

NO TIME-OF-DAY
RESTRICTIONS

No food

CAN BE TAKEN WITH OR WITHOUT FOOD

Risk of drug

FEW SIGNIFICANT DRUG-DRUG INTERACTIONS

  • Minimal effect on metabolism via the CYP3A4 pathway
  • No known interactions with contraceptives, antihypertensives, proton pump inhibitors, statins, PDE-5 inhibitors or recreational drugs
  • Avoid chronic co-administration of sorbitol and similar solutions
  • Dose adjustment of metformin may be required
  • Dose adjustment of DTG required for rifampicin, carbamazepine, oxcarbazepine, phenytoin, phenobarbital and St. John's wort
  • Timing of dose will need to be adjusted if co-administered with polyvalent cation-antacids
  • Timing of dose may need to be adjusted with supplements or multivitamins containing calcium, iron or magnesium
Power reimagined

References:

  1. Cahn P, Sierra Madero J, Arribas J, et al. Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment-naïve adults with HIV-1 infections: 96-week results from the GEMINI studies, Presented at: International AIDS Conference; July 21-24, 2019; Mexico City, Mexico, Slides WEAB0404LB.
  2. Dovato Summary of Product Characteristics. Available at www.medicines.ie. Last Accessed: July 2020

Adverse events should be reported to the Health Products Regulatory Authority (HPRA) using an Adverse Reaction Report Form obtained either from the HPRA or electronically via the website at www.hpra.ie. Adverse reactions can also be reported to the HPRA by calling (01) 6764971. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Trade marks are owned by or licensed to the ViiV Healthcare group of companies.